The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Open accessAbstract
BACKGROUND: Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment. METHODS: In our phase 2, double-blind, placebo-controlled trial, we randomly assigned 142 patients with chronic moderate-to-severe plaque psoriasis to receive subcutaneous injections of 10, 25, 75, or 150 mg of ixekizumab or placebo at 0, 2, 4, 8, 12, and 16 weeks. The primary end point was the proportion of patients with reduction in the psoriasis area-and-severity index (PASI) score by at least 75% at 12 weeks. Secondary end points included the proportion of patients with reduction in the PASI score by at least 90% or by 100%. RESULTS: At 12 weeks, the percentage of patients with a reduction in the PASI score by at least 75% was significantly greater with ixekizumab (except with the lowest, 10-mg dose)--150 mg (82.1%), 75 mg (82.8%), and 25 mg (76.7%)--than with placebo (7.7%, P<0.001 for each comparison), as was the percentage of patients with a reduction in the PASI score by at least 90%: 150 mg (71.4%), 75 mg (58.6%), and 25 mg (50.0%) versus placebo (0%, P<0.001 for each comparison). Similarly, a 100% reduction in the PASI score was achieved in significantly more patients in the 150-mg group (39.3%) and the 75-mg group (37.9%) than in the placebo group (0%) (P<0.001 for both comparisons). Significant differences occurred at as early as 1 week and were sustained through 20 weeks. Adverse events occurred in 63% of patients in both the combined ixekizumab groups and in the placebo group. No serious adverse events or major cardiovascular events were observed. CONCLUSIONS: Use of a humanized anti-interleukin-17 monoclonal antibody, ixekizumab, improved the clinical symptoms of psoriasis. Further studies are needed to establish its long-term safety and efficacy in patients with psoriasis. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT01107457.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Interleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Self-citationPapp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationNeutrophil Recruitment by Human IL-17 Via C-X-C Chemokine Release in the Airways
Laan, M., Cui, Z.-H., Hoshino, H., Lötvall, J., Sjöstrand, M., Gruenert, D. C., Skoogh, B.-E., & Lindén, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2347 · Cited by 880
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Cited by
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationBrodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationTeng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Self-citationIL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Dialogue between skin microbiota and immunity
Belkaid, Y., & Segre, J. A. (2014) · Science · doi:10.1126/science.1260144 · Cited by 749
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Mease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., Lin, C.-Y., Braun, D. K., Lee, C. H., & Gladman, D. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209709 · Cited by 580
Self-citationTherapeutic opportunities of the IL-22–IL-22R1 system
Sabat, R., Ouyang, W., & Wolk, K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4176 · Cited by 562
IL-17 receptor–based signaling and implications for disease
Li, X., Bechara, R., Zhao, J., McGeachy, M. J., & Gaffen, S. L. (2019) · Nature Immunology · doi:10.1038/s41590-019-0514-y · Cited by 548
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Kaymaz, K., & Beikler, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143394 · Cited by 534
Innate lymphoid cells in the initiation, regulation and resolution of inflammation
Sonnenberg, G. F., & Artis, D. (2015) · Nature Medicine · doi:10.1038/nm.3892 · Cited by 503
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
The IL-23-IL-17 axis in inflammatory arthritis
Lubberts, E. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.53 · Cited by 442
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405
Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
Cheuk, S., Wikén, M., Blomqvist, L., Nylén, S., Talme, T., Ståhle, M., & Eidsmo, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302313 · Cited by 413
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Scher, J. U., Ogdie, A., Merola, J. F., & Ritchlin, C. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0175-0 · Cited by 394
Atreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3462 · Cited by 392
New anti-inflammatory targets for chronic obstructive pulmonary disease
Barnes, P. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4025 · Cited by 392
CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity
Wang, C., Yosef, N., Gaublomme, J., Wu, C., Lee, Y., Clish, C. B., Kaminski, J., Xiao, S., Zu Horste, G. M., Pawlak, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.068 · Cited by 392
New insights of T cells in the pathogenesis of psoriasis
Cai, Y., Fleming, C., & Yan, J. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.15 · Cited by 389
Compartmentalized and systemic control of tissue immunity by commensals
Belkaid, Y., & Naik, S. (2013) · Nature Immunology · doi:10.1038/ni.2604 · Cited by 382
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez-Fariñas, M., Haslett, P. A., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383
Self-citationBaliwag, J., Barnes, D. H., & Johnston, A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.014 · Cited by 373
Fowler, V. G., Allen, K. B., Moreira, E. D., Moustafa, M., Isgro, F., Boucher, H. W., Corey, G. R., Carmeli, Y., Betts, R., Hartzel, J. S., et al. (2013) · JAMA · doi:10.1001/jama.2013.3010 · Cited by 372
Diagnosis and classification of psoriasis
Raychaudhuri, S. K., Maverakis, E., & Raychaudhuri, S. P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.008 · Cited by 370
Interleukin-17 and innate immunity in infections and chronic inflammation
Isailovic, N., Daigo, K., Mantovani, A., & Selmi, C. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.006 · Cited by 363
Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., Haemmerle, S., Thurston, H. J., Papavassilis, C., & Richards, H. B. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12110 · Cited by 360
Lotti, F., Jarrar, A. M., Pai, R. K., Hitomi, M., Lathia, J., Mace, A., Gantt, G. A., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 359
Monin, L., & Gaffen, S. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028522 · Cited by 339
Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation
Cader, M. Z., & Kaser, A. (2013) · Gut · doi:10.1136/gutjnl-2012-303955 · Cited by 337
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Lynde, C. W., Poulin, Y., Vender, R., Bourcier, M., & Khalil, S. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.036 · Cited by 335
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
The Immunopathogenesis of Psoriasis
Kim, J., & Krueger, J. G. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2014.09.002 · Cited by 331
Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Rincon, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328
Blauvelt, A., Prinz, J. C., Gottlieb, A. B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13348 · Cited by 323
Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C., Li, K., Campbell, K., Marciniak, S. J., Wasfi, Y., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.025 · Cited by 320
Self-citationDi Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
Effect of IL-17A blockade with secukinumab in autoimmune diseases
Patel, D. D., Lee, D. M., Kolbinger, F., & Antoni, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202371 · Cited by 313
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation
Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201505 · Cited by 308
Emerging cell and cytokine targets in rheumatoid arthritis
Burmester, G. R., Feist, E., & Dörner, T. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.168 · Cited by 307
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306
Cytokines and the Skin Barrier
Hänel, K., Cornelissen, C., Lüscher, B., & Baron, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14046720 · Cited by 305
Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
The Role of Epigenetics in Autoimmune/Inflammatory Disease
Surace, A. E. A., & Hedrich, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01525 · Cited by 302
Daiber, A., Xia, N., Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Münzel, T., & Li, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010187 · Cited by 297
Mitroulis, I., Alexaki, V. I., Kourtzelis, I., Ziogas, A., Hajishengallis, G., & Chavakis, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.008 · Cited by 283
Innate Lymphoid Cell Interactions with Microbiota: Implications for Intestinal Health and Disease
Sonnenberg, G. F., & Artis, D. (2012) · Immunity · doi:10.1016/j.immuni.2012.10.003 · Cited by 277
Xiao, S., Yosef, N., Yang, J., Wang, Y., Zhou, L., Zhu, C., Wu, C., Baloglu, E., Schmidt, D., Ramesh, R., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.004 · Cited by 276
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Saunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Self-citationCurrent knowledge on psoriasis and autoimmune diseases
McCormick, T., Ayala-Fontanez, N., & Soler, D. (2016) · Psoriasis: Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 266
Langley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Karbach, S., Croxford, A. L., Oelze, M., Schüler, R., Minwegen, D., Wegner, J., Koukes, L., Yogev, N., Nikolaev, A., Reißig, S., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304108 · Cited by 261
IL-17 and Th17 Cells in Atherosclerosis: Subtle and Contextual Roles
Taleb, S., Tedgui, A., & Mallat, Z. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303567 · Cited by 260
Krueger, J. G., Ferris, L. K., Menter, A., Wagner, F., White, A., Visvanathan, S., Lalovic, B., Aslanyan, S., Wang, E. E. L., Hall, D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.018 · Cited by 256
T cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Biologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211
“While concomitant therapies may have contributed to these findings, the role of IL-17A inhibition in the observed decreases in mean neutrophil counts in these patients is unclear, since no change in mean neutrophil counts was observed in a 12-week study of ixekizumab in psoriasis patients (29).”
BackgroundThe Role of Th17-Related Cytokines in Atopic Dermatitis
Sugaya, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041314 · Cited by 204
IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells
Bär, E., Whitney, P. G., Moor, K., Reis e Sousa, C., & LeibundGut-Landmann, S. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.002 · Cited by 197
Etiology and Pathogenesis of Psoriasis
Boehncke, W.-H. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.07.013 · Cited by 197
Current Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163
IL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling
Garg, A. V., Ahmed, M., Vallejo, A. N., Ma, A., & Gaffen, S. L. (2013) · Science Signaling · doi:10.1126/scisignal.2003699 · Cited by 128
Berry, S. P. D.-G., Dossou, C., Kashif, A., Sharifinejad, N., Azizi, G., Hamedifar, H., Sabzvari, A., & Zian, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108402 · Cited by 124
Immunology of neuromyelitis optica: a T cell-B cell collaboration
Mitsdoerffer, M., Kuchroo, V., & Korn, T. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12118 · Cited by 91
MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation
Monin, L., Gudjonsson, J. E., Childs, E. E., Amatya, N., Xing, X., Verma, A. H., Coleman, B. M., Garg, A. V., Killeen, M., Mathers, A., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601551 · Cited by 82
Chimenti, M. S., Sunzini, F., Fiorucci, L., Botti, E., Fonti, G. L., Conigliaro, P., Triggianese, P., Costa, L., Caso, F., Giunta, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02363 · Cited by 77
Amatya, N., Childs, E. E., Cruz, J. A., Aggor, F. E. Y., Garg, A. V., Berman, A. J., Gudjonsson, J. E., Atasoy, U., & Gaffen, S. L. (2018) · Science Signaling · doi:10.1126/scisignal.aat4617 · Cited by 75
“Blocking IL-17 is remarkably effective in treating psoriasis and is under evaluation for other autoimmune conditions (59, 60).”
BackgroundInterleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis
Ferreira, M. C., Whibley, N., Mamo, A. J., Siebenlist, U., Chan, Y. R., & Gaffen, S. L. (2014) · Infection and Immunity · doi:10.1128/iai.01389-13 · Cited by 72
Schaper, K., Dickhaut, J., Japtok, L., Kietzmann, M., Mischke, R., Kleuser, B., & Bäumer, W. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.03.006 · Cited by 68
The origin and role of innate lymphoid cells in the lung
Lai, D.-M., Shu, Q., & Fan, J. (2016) · Military Medical Research · doi:10.1186/s40779-016-0093-2 · Cited by 45
Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice
Neu, S. D., Strzepa, A., Martin, D., Sorci-Thomas, M. G., Pritchard, K. A., & Dittel, B. N. (2021) · Antioxidants · doi:10.3390/antiox10091338 · Cited by 40
Update on the role of Interleukin 17 in rheumatologic autoimmune diseases
Konya, C., Paz, Z., Apostolidis, S. A., & Tsokos, G. C. (2015) · Cytokine · doi:10.1016/j.cyto.2015.01.003 · Cited by 35
IL-17 Signaling Triggers Degradation of the Constitutive NF-κB Inhibitor ABIN-1
Cruz, J. A., Childs, E. E., Amatya, N., Garg, A. V., Beyaert, R., Kane, L. P., Aneskievich, B. J., Ma, A., & Gaffen, S. L. (2017) · ImmunoHorizons · doi:10.4049/immunohorizons.1700035 · Cited by 29
Metadata
- Authors
- Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-29
- Volume
- 366
- Issue
- 13
- Pages
- 1190-1199
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2322390243
- Cited by
- 936
- References
- 24
- FWCI
- 60.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.